Dana-Farber researchers present key studies at ASCO annual meeting

(Dana-Farber Cancer Institute) Dana-Farber Cancer Institute researchers are presenting at the 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO). Toni K. Choueiri, MD, will present results from the randomized, double-blind, phase III KEYNOTE-564 trial evaluating pembrolizumab versus placebo after surgery in patients with renal cell carcinoma during ASCO's Plenary Session.